FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to new immune-stimulating proteins; it can be used in medicine. The invention allows for the production of chimeric proteins that include extracellular domains of transmembrane proteins, including TIGIT and/or LIGHT proteins. Such chimeric proteins are capable of simultaneous suppression of immune-inhibiting signals and stimulation of an immune response in a subject in tumor cells.
EFFECT: invention can be used as a drug in the treatment of cancer diseases.
47 cl, 2 tbl, 10 ex, 32 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| TREATMENT METHODS FOR HEMOPHILIA A | 2019 |
|
RU2812863C2 |
| UNIVERSAL ANTIBODY-MEDIATED BIOSENSOR | 2016 |
|
RU2746486C2 |
| COMBINED THERAPY FOR MALIGNANT TUMOR TREATMENT | 2016 |
|
RU2733315C2 |
